Published on 24/12/2025
Accelerated Clinical Trials in India: CDSCO’s Approach to Fast-Tracking Critical Studies
Introduction
India’s clinical trial landscape has undergone rapid transformation, particularly in response to global health crises and the need for life-saving therapies. The Central Drugs Standard Control Organization (CDSCO), as India’s national regulatory authority, has adapted its frameworks to allow fast-tracking of critical clinical trials without compromising on safety, ethics, or data quality. Whether it’s for vaccines, oncology drugs, orphan therapies, or emergency treatments, the demand for regulatory agility is now a defining feature of India’s drug development ecosystem.
Through provisions under the New Drugs and Clinical Trials Rules (NDCTR), 2019, the CDSCO has introduced mechanisms such as accelerated approvals, waiver of local trials, and emergency use authorizations (EUAs). These tools have played a pivotal role in enabling rapid response to pandemics like COVID-19 and in supporting innovation across therapeutic areas like rare diseases and oncology. This article provides a regulatory deep dive into how fast-tracking works in India, the CDSCO’s role, and best practices for sponsors aiming to leverage these pathways.
Background / Regulatory Framework
NDCTR 2019: Foundation for Fast-Tracking
The NDCTR, notified in March 2019, is India’s unified framework for clinical trials, ethics, and
Emergency Use Authorizations (EUAs)
While NDCTR does not explicitly use the term EUA, CDSCO issued several ad hoc guidance documents during the COVID-19 pandemic that enabled restricted emergency use of vaccines and treatments (e.g., Remdesivir, Covaxin, Covishield). These EUAs were often contingent upon post-marketing surveillance and conditional data submissions.
WHO and ICH Context
Globally, fast-track pathways align with WHO GCP expectations and ICH E6(R2) for maintaining quality while enabling timely access. India’s adoption of similar expedited pathways has aligned it with practices followed by the US FDA (Breakthrough Therapy Designation), EMA (Conditional Approval), and Japan’s PMDA (Sakigake Designation).
Core Clinical Trial Insights
Eligibility for Fast-Track Review in India
The CDSCO may consider fast-tracking trial applications under the following circumstances:
- Therapies targeting life-threatening, serious, or rare diseases
- Drugs already approved by regulators in US, UK, EU, Japan, Australia
- Vaccines during public health emergencies
- Innovative therapies where no alternative exists
Applicants must provide scientific justification and risk-benefit rationale in the application cover letter or pre-submission meeting.
Regulatory Timelines Under Fast-Track Pathway
Under standard NDCTR timelines:
- New Drug Clinical Trial (CT) protocol approval: 90 working days
- Biologic or Vaccine CT approval: 90 working days
- Medical Device trials: 90 working days
Under fast-tracking, CDSCO has granted approvals in as little as 7–21 days during emergencies, particularly when accompanied by foreign regulatory approvals or WHO EUL listing. However, timelines may vary depending on dossier completeness and trial risk categorization.
Fast-Track During COVID-19: Lessons Learned
The COVID-19 pandemic tested the CDSCO’s responsiveness:
- Covaxin: Received restricted emergency use approval in Jan 2021 based on bridging study data.
- Covishield: Received approval based on international trial data and local immunogenicity assessments.
- Remdesivir: Approved under restricted use with strict pharmacovigilance obligations.
These cases demonstrated CDSCO’s ability to evaluate data swiftly without bypassing core ethical and quality checks.
Waiver of Local Clinical Trials
NDCTR Rule 75 allows for waiver of local clinical trials if the drug is approved and marketed in certain countries and if sufficient safety and efficacy data exists. Such waivers are often granted for drugs for rare diseases or unmet needs, especially when no therapy exists in India.
Role of Subject Expert Committees (SECs)
All critical trial applications undergo review by SECs composed of domain experts. For fast-tracked reviews, SECs may meet on short notice, sometimes within 24–72 hours of submission, especially during pandemics or public health emergencies.
Post-Approval Conditions for Fast-Tracked Trials
Drugs and biologics approved through fast-tracked pathways are subject to conditions such as:
- Post-marketing surveillance (Phase 4 studies)
- Real-time adverse event reporting
- Submission of long-term efficacy data
- Limited label indications pending full data
These ensure continued evaluation of safety and benefit-risk ratio after early access approval.
Common Pitfalls for Sponsors
- Submitting incomplete CT dossiers expecting fast-tracking
- Not requesting pre-submission meetings to align expectations
- Failing to align timelines with Ethics Committee approvals
- Delays in pharmacovigilance system readiness post-approval
Best Practices & Preventive Measures
- Request Type A (Pre-Submission) meetings to discuss eligibility for fast-track approval
- Submit complete CT application including global data, literature, and Indian unmet need justification
- Align Ethics Committee review and central submission timelines
- Ensure rapid PV reporting infrastructure is in place post-approval
- Prepare public communication plans for fast-tracked drugs to manage risk perception
Scientific & Regulatory Evidence
- NDCTR 2019: Rule 75, 81, 84 on trial approval timelines and waivers
- CDSCO COVID-19 circulars: Emergency use and trial exemptions (2020–2021)
- ICH E6(R2): Clinical trial oversight and documentation standards
- WHO EUL Pathway: Listing and reliance for vaccines
- EU EMA Conditional Approval: Reference model for India
Special Considerations
India-Specific Regulatory Culture
India’s regulatory culture emphasizes public health priorities, domestic manufacturing capacity, and ethical conduct. Thus, fast-tracked trials are evaluated with heightened attention to post-approval surveillance, especially for vaccines and biosimilars.
Rare Diseases and Orphan Drugs
Sponsors targeting rare conditions may benefit from fast-track review if they can demonstrate unmet need, global approval status, or real-world evidence. India has no separate orphan drug policy, but fast-tracking is used as a workaround.
Public Scrutiny of Fast-Tracked Trials
Due to heightened media and public interest, particularly during COVID-19, sponsors must invest in transparency, patient communication, and scientific rigor to maintain public trust.
When Sponsors Should Seek Regulatory Advice
- Before submitting a fast-track CT application, especially for rare diseases
- When seeking waiver of local trials based on foreign data
- If combining multiple fast-tracked indications (e.g., oncology + rare disease)
- To clarify conditional approval vs full marketing authorization obligations
- For pediatric, vaccine, or first-in-human trials requiring expedited review
FAQs
1. What is the definition of a “critical trial” in India?
There is no fixed legal definition, but it refers to trials involving life-saving drugs, vaccines, or treatments for serious or unmet medical needs.
2. Does CDSCO offer formal fast-track designations?
No, but expedited review is granted on a case-by-case basis, often triggered by global regulatory status and public health needs.
3. Can local trials be waived in fast-track scenarios?
Yes, under Rule 75 if data from US/EU/Japan/Australia/UK is provided, and the drug is already approved and marketed there.
4. What documents are required to request fast-tracking?
A strong justification letter, global data summaries, unmet need statement, and any prior approvals. Requesting a pre-submission meeting is advised.
5. Are Ethics Committees also required to fast-track their reviews?
No formal obligation, but many ECs cooperate in public health emergencies or when requested by institutional leadership.
6. What happens if post-approval obligations are not met?
CDSCO can revoke conditional approval or restrict use. Continued compliance with surveillance and reporting is critical.
Conclusion
India’s CDSCO has shown commendable adaptability in enabling accelerated access to critical therapies, especially during emergencies like COVID-19. Through a blend of NDCTR provisions, ad hoc guidances, and reliance on foreign approvals, the regulatory system supports both innovation and patient safety. However, fast-tracking is not a shortcut—it requires rigorous data, strategic planning, and robust post-approval controls. Sponsors who prepare proactively and align with CDSCO expectations stand to benefit from faster timelines without regulatory compromise.